The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
NLRP3 inflammasome activation drives tau pathology
Open accessAbstract
Alzheimer’s disease is characterized by the accumulation of amyloid-beta in plaques, aggregation of hyperphosphorylated tau in neurofibrillary tangles and neuroinflammation, together resulting in neurodegeneration and cognitive decline1. The NLRP3 inflammasome assembles inside of microglia on activation, leading to increased cleavage and activity of caspase-1 and downstream interleukin-1β release2. Although the NLRP3 inflammasome has been shown to be essential for the development and progression of amyloid-beta pathology in mice3, the precise effect on tau pathology remains unknown. Here we show that loss of NLRP3 inflammasome function reduced tau hyperphosphorylation and aggregation by regulating tau kinases and phosphatases. Tau activated the NLRP3 inflammasome and intracerebral injection of fibrillar amyloid-beta-containing brain homogenates induced tau pathology in an NLRP3-dependent manner. These data identify an important role of microglia and NLRP3 inflammasome activation in the pathogenesis of tauopathies and support the amyloid-cascade hypothesis in Alzheimer’s disease, demonstrating that neurofibrillary tangles develop downstream of amyloid-beta-induced microglial activation. The authors show that NLRP3 inflammasome is activated in microglia of patients with fronto-temporal dementia and in a mouse model of tau pathology, and that the loss of NLRP3 inflammasome function decreases tau pathology and improves cognition in mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The NLRP3-ASC inflammasome mechanisms contributing to increased beta-amyloids and tau are thought to be a combination of kinases and phosphatases involved in tau phosphorylation [96] through the production of IL-1 beta.”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the CNS, inflammasome activation has been mainly linked to neuroinflammatory conditions. As example, it has an essential role in the progression of several neurological disorders like MS, AD, PPD, and NPS (132, 193–197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of hippocampal NLRP3 inflammasome-mediated pyroptosis is associated with neuronal damage, cognitive decline, and neuronal death (Hanslik & Ulland, 2020; Heneka et al., 2013; Ising et al., 2019; Venegas et al., 2017).”
From Picroside II Alleviates the Progression of Alzheimer’s Disease via the NLRP3/Caspase-1/GSDMD Pathway (2025) · cites this paper as Ising et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, treatment of mouse primary hippocampal neurons with conditioned media from wild-type, but not Nlrp3−/− and Asc−/−, microglia primed with LPS resulted in elevated total and phosphorylated tau levels, suggesting that NLRP3 inflammasome activation in microglia can induce tau pathology in neurons.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, several cytokines, including IL-1β and IL-6, can directly induce tau phosphorylation in vitro, thus potentially contributing to the development of tau pathology.54”
From Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist (2024) · cites this paper as [56]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Research by Ising et al. suggests that tau proteins can activate the NLRP3 inflammasome, which then promotes excessive tau phosphorylation and aggregation by affecting specific tau kinases and phosphatases.252”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [252]
The cited source says what the claim attributes to it.
In the citing paper
“In turn, the NLRP3 inflammasome is essential for the development and progression of Aβ pathology in mice29 and may drive tau pathology through Aβ-induced microglial activation30.”
From New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“A recent study shows that NLR family pyrin domain-containing protein 3 (NLRP3) inflammasome activation induces tau hyperphosphorylation and aggregation through modulating tau kinases and phosphatases [159].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [159]
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, microglia could also drive tau spreading and toxicity by promoting neuroinflammation, such as activating NACHT-, LRR- and pyrin (PYD)-domain-containing protein 3 (NLRP3) inflammasome155 or inducing NF-kB signaling.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [155]
The cited source says what the claim attributes to it.
In the citing paper
“Tau oligomers and monomers can also activate NLRP3 inflammasomes, further perpetuating microglial activation [162] and potential progression of tau pathology.”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [162]
The cited source says what the claim attributes to it.
In the citing paper
“Treatment of wild-type primary microglia with recombinant wild-type tau and recombinant tau with a P301S mutation increased IL-1β secretion, an effect that was attenuated in Nlrp3−/− and Asc−/− microglia, suggesting that tau induces IL-1β secretion in a NLRP3-dependent manner [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Inhibiting or downregulating the NLRP3 inflammasome ameliorates AD neuropathology in animal models, which opens up a therapeutic avenue for modulators of NLRP3 activation in AD.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, treatment of mouse primary hippocampal neurons with conditioned media from wild-type, but not Nlrp3−/− and Asc−/−, microglia primed with LPS resulted in elevated total and phosphorylated tau levels, suggesting that NLRP3 inflammasome activation in microglia can induce tau pathology in neurons.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Treatment of wild-type primary microglia with recombinant wild-type tau and recombinant tau with a P301S mutation increased IL-1β secretion, an effect that was attenuated in Nlrp3−/− and Asc−/− microglia, suggesting that tau induces IL-1β secretion in a NLRP3-dependent manner [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“The NLRP3 inflammasome has a bidirectional relationship with AD-related tau pathology as well.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that while some forms of tau can activate the NLRP3 inflammasome, inflammasome activation can exacerbate tau pathology by promoting elevated phosphorylation of tau [81, 82].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, treatment with brain homogenates from APP/PS1 mice induced tau hyperphosphorylation in a mouse model of tau aggregation pathology (Tau22) but not in Tau22/Nlrp3−/− and Tau22/Asc−/− mice, indicating the NLRP3 inflammasome as a mediator of Aβ-induced tau pathology [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, treatment with brain homogenates from APP/PS1 mice induced tau hyperphosphorylation in a mouse model of tau aggregation pathology (Tau22) but not in Tau22/Nlrp3−/− and Tau22/Asc−/− mice, indicating the NLRP3 inflammasome as a mediator of Aβ-induced tau pathology [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that while some forms of tau can activate the NLRP3 inflammasome, inflammasome activation can exacerbate tau pathology by promoting elevated phosphorylation of tau [81, 82].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“In Tau22 mice, ablation of Nlrp3 or Asc reduced levels of hyperphosphorylated tau and tau aggregates and rescued tau-induced spatial memory deficits [81].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [81]
In the citing paper
“Studies have demonstrated important roles of the NLRP3 inflammasome in aging and age-related diseases, such as atherosclerosis metabolic syndrome, type 2 diabetes, and Alzheimer’s disease (81–83).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“For example, in AD and frontotemporal dementia, neuroinflammation and microglia activation potentiate the spreading of pathological tau neurofibrillary tangles (83, 175).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“In AD, this relationship may be mediated by NLRP3 inflammasome activation in microglia, a process that activates tau kinases (e.g., GSK-3β and CaMKII-α) and results in tau hyperphosphorylation (83).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [83]
In the citing paper
“The knockout of ASC or NLRP3 ameliorates AD‐like brain pathology in animal models. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“The activation of the NLRP3 inflammasome drives tau pathology. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“Inflammaging can drive tau pathology and neurodegeneration in AD by impairing the clearance of Aβ peptides, altering BBB integrity, and affecting the synaptic functions. 68”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [68]
In the citing paper
“In general, patients affected by tauopathies showed elevated levels of cleaved caspase-1 and ASC and mature IL-1β in the cortex (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Injecting brain homogenates from APP/PS1 or wild-type mice into the hippocampus of Tau22 mice, induced tau hyperphosphorylation in the hippocampus of Tau22 wild-type but not Tau22/Pycard−/− or Tau22/Nlrp3−/− deficient mice”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“suggesting that NLRP3 activation is upstream the Aβ-tau cascade and tau pathology (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Consistent with this, Tau22 mice lacking ASC or NLRP3 expression had lower levels of aggregated and hyperphosphorylated tau in the hippocampus, and their typical spatial memory deficits were rescued (197).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Also, Tau22 mice, another model of AD and other tauopathies, had increased levels of cleaved caspase-1 and ASC in their brain at the age of 11 months compared to their 3-month-old counterparts.”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [197]
In the citing paper
“Further, activated microglia promote tau phosphorylation and aggregation by activation of the NLRP3 (nucleotide binding oligomerisation domain (NOD)-, leucine-rich repeat (LRR)- and pyrin domain-containing protein 3) inflammasome in response to amyloid-β [22,23].”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“Further, there is evidence tauopathy is driven by NLRP3 inflammasome activation in microglia in response to amyloid-β [23].”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“ROS from NOX4 also contribute to activation of the NLRP3 inflammasome, a driver of both amyloid-β [156] and tau [23] pathology.”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [23]
In the citing paper
“Growing evidence indicates that Aβ accumulation stimulates tau phosphorylation and fibrillary tangle formation, leading to the process of neurodegeneration.112–114”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [112]
In the citing paper
“In particular, microglial NLRP3 has been shown to be a major driver of amyloid beta and tau toxicity in AD, suggesting its activation has important implications for disease progression (Halle et al, 2008; Venegas et al, 2017; Ising et al, 2019).”
From Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease (2022) · cites this paper as Ising et al, 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Szklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N. T., Roth, A., Bork, P., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw937 · Cited by 6,980
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898
Self-citationThe NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Self-citationDepletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3
Kanneganti, T., Özören, N., Body–Malapel, M., Amer, A. O., Park, J., Franchi, L., Whitfield, J. R., Barchet, W., Colonna, M., Vandenabeele, P., et al. (2006) · Nature · doi:10.1038/nature04517 · Cited by 1,149
Tau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037
Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease
Venegas, C., Kumar, S., Franklin, B. S., Dierkes, T., Brinkschulte, R., Tejera, D., Vieira-Saecker, A., Schwartz, S., Santarelli, F., Kummer, M. P., et al. (2017) · Nature · doi:10.1038/nature25158 · Cited by 983
Self-citationInflammasome signalling in brain function and neurodegenerative disease
Heneka, M. T., McManus, R. M., & Latz, E. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0055-7 · Cited by 836
Self-citationCanonical Nlrp3 Inflammasome Links Systemic Low-Grade Inflammation to Functional Decline in Aging
Youm, Y.-H., Grant, R. W., McCabe, L. R., Albarado, D. C., Nguyen, K. Y., Ravussin, A., Pistell, P., Newman, S., Carter, R., Laque, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.09.010 · Cited by 674
Cited by
Sorted by citations
Items 201–300 of 1,003
Immune Activation in Alzheimer Disease
Mary, A., Mancuso, R., & Heneka, M. T. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101921-035222 · Cited by 82
Self-citationAstrocytic propagation of Tau in the context of Alzheimer's disease
Fleeman, R. M., & Proctor, E. A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.645233 · Cited by 75
Hole, K. L., & Williams, R. J. (2020) · Brain Plasticity · doi:10.3233/bpl-200098 · Cited by 81
Targeting NLRP3 inflammasome for neurodegenerative disorders
Yao, J., Wang, Z., Song, W., & Zhang, Y. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02239-0 · Cited by 81
Danger-Sensing/Patten Recognition Receptors and Neuroinflammation in Alzheimer’s Disease
Chiarini, A., Armato, U., Hu, P., & Prà, I. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239036 · Cited by 77
Imaging Neuroinflammation in Neurodegenerative Disorders
Masdeu, J. C., Pascual, B., & Fujita, M. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263200 · Cited by 77
The impact of neuroinflammation on neuronal integrity
Tastan, B., & Heneka, M. T. (2024) · Immunological Reviews · doi:10.1111/imr.13419 · Cited by 81
Self-citationTargeting Inflammasomes to Treat Neurological Diseases
Lünemann, J. D., Malhotra, S., Shinohara, M. L., Montalbán, X., & Comabella, M. (2021) · Annals of Neurology · doi:10.1002/ana.26158 · Cited by 73
Inflammasome activation in traumatic brain injury and Alzheimer's disease
Johnson, N. H., Vaccari, J. P. D. R., Bramlett, H. M., Keane, R. W., & Dietrich, W. D. (2022) · Translational research · doi:10.1016/j.trsl.2022.08.014 · Cited by 74
The NLRP3 inflammasome modulates tau pathology and neurodegeneration in a tauopathy model
Stancu, I. C., Lodder, C., Botella Lucena, P., Vanherle, S., Gutiérrez de Ravé, M., Terwel, D., Bottelbergs, A., & Dewachter, I. (2022) · Glia · doi:10.1002/glia.24160 · Cited by 72
Astrocyte senescence and SASP in neurodegeneration: tau joins the loop
Ungerleider, K., Beck, J. A., Lissa, D., Turnquist, C., Horikawa, I., Harris, B. T., & Harris, C. C. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1909260 · Cited by 72
The Role of the Effects of Autophagy on NLRP3 Inflammasome in Inflammatory Nervous System Diseases
Zhao, S., Li, X., Wang, J., & Wang, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.657478 · Cited by 72
Lodder, C., Scheyltjens, I., Stancu, I., Lucena, P. B., de Ravé, M. G., Vanherle, S., Vanmierlo, T., Cremers, N., Vanrusselt, H., Brône, B., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01204-8 · Cited by 71
Dimethyl fumarate: A review of preclinical efficacy in models of neurodegenerative diseases
Majkutewicz, I. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175025 · Cited by 79
Targeting NLRP3-Mediated Neuroinflammation in Alzheimer’s Disease Treatment
Barczuk, J., Siwecka, N., Lusa, W., Rozpędek‐Kamińska, W., Kucharska, E., & Majsterek, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168979 · Cited by 76
Melchiorri, D., Merlo, S., Micallef, B., Borg, J.-J., & Dráfi, F. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1196413 · Cited by 73
Targeting Microglia in Alzheimer’s Disease: Pathogenesis and Potential Therapeutic Strategies
Sun, Z., Zhang, X., So, K.-F., Jiang, W., & Chiu, K. (2024) · Biomolecules · doi:10.3390/biom14070833 · Cited by 71
Yang, H., Oh, C.-K., Amal, H., Wishnok, J. S., Lewis, S., Schahrer, E., Trudler, D., Nakamura, T., Tannenbaum, S. R., & Lipton, S. A. (2022) · Science Advances · doi:10.1126/sciadv.ade0764 · Cited by 70
Das, R. R., & Chinnathambi, S. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.09.024 · Cited by 71
A Multilevel View of the Development of Alzheimer’s Disease
Ávila, J., & Perry, G. L. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.11.015 · Cited by 69
Feng, X., Zhan, F., Luo, D., Hu, J., Wei, G., Hua, F., & Xu, G. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.08.230 · Cited by 66
Rui, W., Xiao, H., Fan, Y., Ma, Z., Xiao, M., Li, S., & Shi, J. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02329-2 · Cited by 79
Ribarič, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063245 · Cited by 77
Chen, K., Wang, H., Ilyas, I., Mahmood, A., & Hou, L. (2023) · Brain Sciences · doi:10.3390/brainsci13040634 · Cited by 82
Qiao, Y., Chi, Y., Zhang, Q., & Ma, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1169499 · Cited by 78
The Role of P2X7 Receptor in Alzheimer’s Disease
Francistiová, L., Bianchi, C., Lauro, C. D., Sebastián‐Serrano, Á., de Diego-García, L., Kobolák, J., Dinnyés, A., & Díaz-Hernández, M. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00094 · Cited by 73
Interleukin-10 deficiency exacerbates inflammation-induced tau pathology
Weston, L. L., Jiang, S., Chisholm, D., Jantzie, L. L., & Bhaskar, K. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02211-1 · Cited by 69
Cao, S., Fisher, D. W., Rodríguez, G., Yu, T., & Dong, H. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02054-2 · Cited by 69
Cognitive dysfunction following COVID-19 infection
Hadad, R., Khoury, J., Stanger, C., Fisher, T., Schneer, S., Ben‐Hayun, R., Possin, K. L., Valcour, V., Aharon‐Peretz, J., & Adir, Y. (2022) · Journal of NeuroVirology · doi:10.1007/s13365-022-01079-y · Cited by 82
Zou, B., Li, J., Ma, R., Cheng, X.-Y., Ma, R.-Y., Zhou, T.-Y., Wu, Z., Yao, Y., & Li, J. (2023) · Aging and Disease · doi:10.14336/ad.2022.1127 · Cited by 76
Ebrahim, N., AlSaihati, H., Alali, Z., Aleniz, F. Q., Mahmoud, S. Y., Badr, O. A. M., Dessouky, A. A., Mostafa, O., Hussien, N. I., Farid, A. S., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116836 · Cited by 69
RetractedAnti-Inflammatory Role of the Klotho Protein and Relevance to Aging
Prud’homme, G. J., & Wang, Q. (2024) · Cells · doi:10.3390/cells13171413 · Cited by 79
Siddik, M. A. B., Mullins, C. A., Kramer, A., Shah, H., Gannaban, R. B., Zabet-Moghaddam, M., Huebinger, R. M., Hegde, V. K., MohanKumar, S. M. J., MohanKumar, P. S., et al. (2022) · Cells · doi:10.3390/cells11213523 · Cited by 68
Brain Parenchymal and Extraparenchymal Macrophages in Development, Homeostasis, and Disease
Brioschi, S., Zhou, Y., & Colonna, M. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900821 · Cited by 67
Luís, J. P., Simões, C. J. V., & Brito, R. M. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031731 · Cited by 74
Iorio, R., Celenza, G., & Petricca, S. (2022) · Antioxidants · doi:10.3390/antiox11061199 · Cited by 75
Microglial Activation and Priming in Alzheimer’s Disease: State of the Art and Future Perspectives
Bivona, G., Iemmolo, M., Agnello, L., Sasso, B. L., Gambino, C. M., Giglio, R. V., Scazzone, C., Ghersi, G., & Ciaccio, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010884 · Cited by 74
McManus, R. M., Komes, M. P., Griep, A., Santarelli, F., Schwartz, S., Perea, J. R., Schlachetzki, J. C. M., Bouvier, D. S., Khalil, M., Lauterbach, M., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.01.007 · Cited by 81
Self-citationShi, Y., Tao, M., Chen, H., Ma, X., Wang, Y., Hu, Y., Zhou, X. C., Li, J., Cui, B., Qiu, A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.11.027 · Cited by 72
Yang, Y., Wu, L., Chen, J., Wu, X., Xia, J., Meng, Z., Liu, X., & Lin, H. (2020) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2020.038 · Cited by 66
Madhu, L. N., Kodali, M., Upadhya, R., Rao, S., Somayaji, Y., Attaluri, S., Shuai, B., Kirmani, M., Gupta, S., Maness, N., et al. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12519 · Cited by 69
Neuroinflammatory Biomarkers in Alzheimer’s Disease: From Pathophysiology to Clinical Implications
Roveta, F., Bonino, L., Piella, E. M., Rainero, I., & Rubino, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211941 · Cited by 80
Yoon, S.-H., Kim, C., Lee, E., Lee, C., Lee, K.-S., Lee, J., Park, H., Choi, B., Hwang, I., Kim, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56097-1 · Cited by 78
Modulation of Glial Function in Health, Aging, and Neurodegenerative Disease
Hanslik, K. L., Marino, K. M., & Ulland, T. K. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.718324 · Cited by 69
Brosseron, F., Maaß, A., Kleineidam, L., Ravichandran, K. A., García‐González, P., McManus, R. M., Ising, C., Santarelli, F., Kolbe, C., Häsler, L. M., et al. (2022) · Neuron · doi:10.1016/j.neuron.2021.12.016 · Cited by 65
Self-citationNLRP3 inflammasome in health and disease (Review)
Wang, H., Ma, L., Su, W., Liu, Y., Xie, N., & Liu, J. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5489 · Cited by 70
FRET-based Tau seeding assay does not represent prion-like templated assembly of Tau filaments
Kaniyappan, S., Tepper, K., Biernat, J., Chandupatla, R., Hübschmann, S., Irsen, S. H., Bicher, S., Klatt, C., Mandelkow, E., & Mandelkow�, E. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00389-1 · Cited by 65
Kim, D. W., Tu, K. J., Wei, A., Lau, A., Gonzalez-Gil, A., Cao, T., Braunstein, K. E., Ling, J. P., Troncoso, J. C., Wong, P. C., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00589-x · Cited by 71
Ferroptosis, Pyroptosis, and Cuproptosis in Alzheimer’s Disease
Wang, Q., Sun, J., Chen, T., Song, S., Hou, Y., Feng, L., Fan, C., & Li, M. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00343 · Cited by 65
Wang, H., Yang, F., Xin, R., Cui, D., He, J., Zhang, S., & Sun, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110449 · Cited by 64
Self-citationIn Vivo Assessment of Neuroinflammation in 4‐Repeat Tauopathies
Palleis, C., Sauerbeck, J., Beyer, L., Harris, S., Schmitt, J., Morenas‐Rodriguez, E., Finze, A., Nitschmann, A., Ruch‐Rubinstein, F., Eckenweber, F., et al. (2021) · Movement Disorders · doi:10.1002/mds.28395 · Cited by 62
Microglial Function and Regulation during Development, Homeostasis and Alzheimer’s Disease
Casali, B. T., & Reed-Geaghan, E. G. (2021) · Cells · doi:10.3390/cells10040957 · Cited by 70
Kim, S., Kim, D. K., Jeong, S., & Lee, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115894 · Cited by 71
Wang, M., Tang, G., Zhou, C., Guo, H., Hu, Z., Hu, Q., & Li, G. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110387 · Cited by 62
Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline
Peretti, D. E., Boccalini, C., Ribaldi, F., Scheffler, M., Marizzoni, M., Ashton, N. J., Zetterberg, H., Blennow, K., Frisoni, G. B., & Garibotto, V. (2024) · Brain · doi:10.1093/brain/awae211 · Cited by 67
(ADNI), A. D. N. I., Kleineidam, L., Chouraki, V., Próchnicki, T., van der Lee, S. J., Madrid-Márquez, L., Wagner-Thelen, H., Karaca, I., Weinhold, L., Wolfsgruber, S., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02138-6 · Cited by 62
Self-citationAshrafizadeh, M., Najafi, M., Kaviyani, N., Mohammadinejad, R., Farkhondeh, T., & Samarghandian, S. (2021) · Inflammation · doi:10.1007/s10753-021-01428-9 · Cited by 66
RetractedXu, Y., Au, N. P. B., & Ma, C. H. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.896852 · Cited by 68
The COVID-19 pandemic and Alzheimer’s disease: mutual risks and mechanisms
Chen, F., Chen, Y., Wang, Y., Ke, Q., & Cui, L. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00316-y · Cited by 63
Qiu, Y., Shen, X., Ravid, O., Atrakchi, D., Rand, D., Wight, A. E., Kim, H.-J., Zaltsman, S. L., Cooper, I., Beeri, M. S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218915120 · Cited by 62
Liu, P., Zhou, Y., Shi, J.-Z., Wang, F., Yang, X., Zheng, X., Wang, Y., He, Y., Xie, X., & Pang, X. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154801 · Cited by 67
Choi, S.-B., Kwon, S., Kim, J.-H., Ahn, N.-H., Lee, J.-H., & Yang, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411757 · Cited by 65
Li, H., Cai, R., Zhou, Y., Jiang, Y., & Tan, S. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03563-8 · Cited by 72
Chiarini, A., Gui, L., Viviani, C., Armato, U., & Prà, I. D. (2023) · Biomedicines · doi:10.3390/biomedicines11040999 · Cited by 62
Wang, Z., Liu, J., Han, J., Zhang, T., Li, S., Hou, Y., Su, H., Han, F., & Zhang, C. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03166-9 · Cited by 60
Lee, J., Kim, H., Kim, J., Yook, T. H., Kim, K. H., Lee, J. Y., & Yang, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031324 · Cited by 61
Tan, S.-W., Zhao, Y., Li, P., Ning, Y., Huang, Z.-Z., Yang, N., Liu, D., & Zhou, Y. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02274-0 · Cited by 59
Hulse, J. P., & Bhaskar, K. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.805169 · Cited by 63
Faridar, A., Vasquez, M., Thome, A. D., Yin, Z., Xuan, H., Wang, J. H., Wen, S., Li, X., Thonhoff, J. R., Zhao, W., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01447-z · Cited by 64
Tian, H., Huang, B., Nie, H., Chen, X., Zhou, Y., Yang, T., Cheng, S., Mei, Z., & Ge, J. (2023) · Brain Sciences · doi:10.3390/brainsci13101367 · Cited by 58
Target Dysbiosis of Gut Microbes as a Future Therapeutic Manipulation in Alzheimer’s Disease
Zhu, F., Li, C., Chu, F., Tian, X., & Zhu, J. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.544235 · Cited by 59
Fernando, K., & Wijayasinghe, Y. S. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.746631 · Cited by 57
Tang, J., Li, T., Xiong, X., Yang, Q., Su, Z., Zheng, M., & Chen, Q. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02228-z · Cited by 64
Appleton, J., Finn, Q., Zanotti-Fregonara, P., Yu, M., Faridar, A., Nakawah, M. O., Zarate, C., Carrillo, M. C., Dickerson, B. C., Rabinovici, G. D., et al. (2025) · Brain · doi:10.1093/brain/awae234 · Cited by 58
Zhang, L., Xiao, F., Zhang, J., Wang, X., Ying, J., Wei, G., Chen, S., Huang, X., Yu, W., Liu, X., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.646265 · Cited by 57
Zhou, Z., Gong, F., Zhang, P., Wang, X., Zhang, R., Xia, W., Gao, X., Zhou, X., & Cheng, L. (2021) · Nano Research · doi:10.1007/s12274-021-3864-3 · Cited by 60
DAMPs in immunosenescence and cancer
Chen, F., Tang, H., Cai, X., Lin, J., Kang, R., Tang, D., & Liu, J. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.09.005 · Cited by 60
Storelli, F., Billington, S. F., Kumar, A. R., & Unadkat, J. D. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2035 · Cited by 60
Friedland, R. P., McMillan, J. D., & Kurlawala, Z. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051652 · Cited by 56
Inflammasomes and Cell Death: Common Pathways in Microparticle Diseases
Rashidi, M., Wicks, I. P., & Vince, J. E. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.06.005 · Cited by 58
Pathological and Therapeutic Advances in Parkinson’s Disease: Mitochondria in the Interplay
Naren, P., Cholkar, A., Kamble, S., Khan, S. S., Srivastava, S., Madan, J., Mehra, N. K., Tiwari, V., Singh, S. B., & Khatri, D. K. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220682 · Cited by 60
Inflammation promotes synucleinopathy propagation
Kim, T.-K., Bae, E.-J., Jung, B. C., Choi, M.-S., Shin, S. J., Park, S. J., Kim, J. T., Jung, M. K., Ulusoy, A., Song, M., et al. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00895-w · Cited by 61
Li, J., Zhao, R., Jiang, Y., Xu, Y., Zhao, H., Lyu, X., & Wu, T. (2020) · Food & Function · doi:10.1039/c9fo02103e · Cited by 56
Vandendriessche, C., Balusu, S., Cauwenberghe, C. V., Brkić, M., Pauwels, M. J., Plehiers, N., Bruggeman, A., Dujardin, P., Imschoot, G. V., Wonterghem, E. V., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01245-z · Cited by 58
Death Receptors and Their Ligands in Inflammatory Disease and CancerPreprint
Annibaldi, A., & Walczak, H. (2020) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a036384 · Cited by 61
Microglial Immunometabolism in Alzheimer’s Disease
Shippy, D. C., & Ulland, T. K. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.563446 · Cited by 56
Cordaro, M., Salinaro, A. T., Siracusa, R., D’Amico, R., Impellizzeri, D., Scuto, M. C., Ontario, M. L., Cuzzocrea, S., Paola, R. D., Fusco, R., et al. (2021) · Antioxidants · doi:10.3390/antiox10111664 · Cited by 57
Xu, J., Zheng, Y., Zhao, Y., Zhang, Y., Li, H., Zhang, A., Wang, X., Wang, W., Hou, Y., & Wang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.817572 · Cited by 61
Ginsenoside and Its Therapeutic Potential for Cognitive Impairment
Feng, H., Xue, M., Deng, H., Cheng, S., Hu, Y., & Zhou, C. (2022) · Biomolecules · doi:10.3390/biom12091310 · Cited by 58
Recent advancement in therapeutic strategies for Alzheimer’s disease: Insights from clinical trials
Khan, T., Waseem, R., Shahid, M., Ansari, J., Ahanger, I. A., Hassan, M. I., & Islam, A. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102113 · Cited by 60
Kulas, J. A., Weigel, T. K., & Ferris, H. A. (2020) · Drug Development Research · doi:10.1002/ddr.21643 · Cited by 57
McCarty, M. F., Assanga, S. B. I., Luján, L. M. L., O’Keefe, J. H., & DiNicolantonio, J. J. (2020) · Nutrients · doi:10.3390/nu13010047 · Cited by 55
Targeting MicroRNA-485-3p Blocks Alzheimer’s Disease Progression
Koh, H., Lee, S., Lee, H., Min, J.-W., Iwatsubo, T., Teunissen, C. E., Cho, H., & Ryu, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313136 · Cited by 58
Biel, D., Suárez‐Calvet, M., Hager, P., Rubinski, A., Dewenter, A., Steward, A., Roemer, S. N., Ewers, M., Haass, C., Brendel, M., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202216987 · Cited by 56
Panda, C., Voelz, C., Habib, P., Mevissen, C., Pufe, T., Beyer, C., Gupta, S. K., & Slowik, A. (2021) · Cells · doi:10.3390/cells10071652 · Cited by 54
Inflammation: major denominator of obesity, Type 2 diabetes and Alzheimer’s disease-like pathology?
Kacířová, M., Zmeškalová, A., Kořínková, L., Železná, B., Kuneš, J., & Maletı́nská, L. (2020) · Clinical Science · doi:10.1042/cs20191313 · Cited by 56
Aging-Dependent Mitophagy Dysfunction in Alzheimer’s Disease
Song, M., Zhao, X., & Song, F. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02248-y · Cited by 59
Li, X., Zhang, Y., Li, B., Yang, H., Cui, J., Li, X., Zhang, X., Sun, H., Meng, Q., Wu, S., et al. (2020) · Environment International · doi:10.1016/j.envint.2020.105487 · Cited by 53
Biechele, G., Franzmeier, N., Blume, T., Ewers, M., Medina-Luque, J., Eckenweber, F., Sacher, C., Beyer, L., Ruch, F., Lindner, S., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02046-2 · Cited by 53
New hopes for disease modification in Parkinson's Disease
Poewe, W. H., Seppi, K., Marini, K., & Mahlknecht, P. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108085 · Cited by 53
Metadata
- Authors
- Ising, C., Venegas, C., Zhang, S., Scheiblich, H., Schmidt, S. V., Vieira-Saecker, A., Schwartz, S., Albasset, S., McManus, R. M., Tejera, D., Griep, A., Santarelli, F., Brosseron, F., Opitz, S., Stunden, J., Merten, M., Kayed, R., Golenbock, D. T., Blum, D., Latz, E., Buée, L., & Heneka, M. T.
- Affiliations
- University Hospital Bonn (DE)
- German Center for Neurodegenerative Diseases (DE)
- The University of Texas Medical Branch at Galveston (US)
- University of Massachusetts Chan Medical School (US)
- Inserm (FR)
- Corresponding author
- Heneka, Michael T.
- ORCID
- Venue
- Nature
- Published
- 2019-11-20
- Volume
- 575
- Issue
- 7784
- Pages
- 669-673
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7324015
- OpenAlex
- W2990312754
- Semantic Scholar
- 6a9d745a33a2d013c621f57586d9d719671530a7
- Cited by
- 1,487
- References
- 28
- Citations by year
- 2026: 189 · 2025: 226 · 2024: 255 · 2023: 226 · 2022: 248 · 2021: 193 · 2020: 143 · 2019: 3
- FWCI
- 101.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Institutional Repository of the University of Granada (University of Granada) (submittedVersion, cc-by-nc-nd)
- DZNE Pub (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (R01 AG059752-02)
- Agence Nationale de la Recherche (ANR-11-LABX-0009)
- Deutsches Zentrum für Neurodegenerative Erkrankungen
- National Institutes of Health
- National Institute on Aging (R01AG059752, R01AG054025)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- NLRP3 inflammasome, tau hyperphosphorylation, tau aggregation, neurofibrillary tangles, Alzheimer's disease, amyloid-beta, microglia, amyloid hypothesis, frontotemporal dementia, neuroinflammation, caspase-1, IL-1β
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Gene Expression Regulation, Humans, Mice, Inbred C57BL, Phosphorylation, tau Proteins, Microglia, Cyclin-Dependent Kinase 5, Mice, Inflammasomes, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
